Skin prick tests are a common method for diagnosing allergies in pediatric allergy clinics. Unfortunately, these tests can be distressing for children, causing pain and fear that can make them challenging to conduct. Virtual reality (VR) can be used to distract children during medical procedures. This study examines the effect of VR on skin prick test-related pain and fear in children. This parallel-group, single-blind, prospective, randomized controlled trial enrolled 233 children evaluated at the Pediatric Allergy Clinic and scheduled to undergo skin prick testing between March and June 2024. Among these children, 75 children aged 4–10 years who met the inclusion criteria were divided into two groups as VR group (n = 25) and control group (n = 25) by block randomization using gender and age group variables. The VR group wore VR goggles during the skin prick test, while the control group underwent the standard procedure. Pain and fear levels were assessed using the Wong-Baker FACES® Pain Scale and the Child Fear Scale. Children in the VR group exhibited a significant reduction in pain and fear levels associated with the skin prick test experience compared to the control group, as evaluated by children, parents, and researchers (p < 0.05). No side effects related to VR were reported. Conclusion: Virtual reality can be an effective tool in pediatric allergy clinics to reduce pain and fear during skin prick testing. By enhancing the child’s comfort, VR may also improve adherence to allergy follow-up and treatment, ultimately contributing to better clinical outcomes. What is Known:• Children often experience significant pain and fear during invasive procedures such as skin prick tests, and distraction methods have been shown to reduce pain and anxiety.What is New:• This study is the first randomized controlled trial to demonstrate that virtual reality (VR) significantly reduces pain and fear during skin prick tests in children.• This study supports the integration of new technologies such as VR as a standard practice for managing pain and fear during skin prick tests in pediatric allergy clinics.Trial registration: The clinical trial registration number is NCT06421779. Study start date: March 22, 2024. Study completion date: July 22, 2024. (https://clinicaltrials.gov/study/NCT06421779). Graphical Abstract
2 January 2026 in Pediatric Allergy and Immunology
We report a pilot study that revealed concerning blind spots in the conceptualization of medical safety requirements by artificial intelligence (AI). During routine skin testing, a patient experienced anaphylaxis. Although the event was managed effectively, crucial time was lost while staff searched for a pulse oximeter that was stored away from the bedside. This incident highlights global variability in safety practices across allergy testing facilities, despite international guidelines that mandate the immediate availability of emergency equipment [1]. We therefore explored whether AI could contribute to standardizing safety assessments of allergy testing rooms. We conducted a three-phase pilot study evaluating AI's baseline understanding of allergy test room requirements and its potential utility as a safety assessment tool following expert training. 1) Phase 1: Using GPT-4o's integrated image generation, we prompted, "Generate a photorealistic image of an allergy test room in a modern outpatient clinic, showing the full room layout. " A single image was generated using GPT-4o (May 2024 version) with default parameters (temperature = 1.0, no seed specification) (Figure 1). This zero-shot approach intentionally avoided iterative refinement in order to capture the AI's baseline conceptualization. For reproducibility, the same prompt consistently produces images with similar omissions of safety equipment, although specific aesthetic details vary.
Background/Objectives: Biphasic reactions are an important consideration during post-treatment observation of children with anaphylaxis; however, real-world pediatric data on observation practices and the timing of these reactions remain limited. This study aimed to describe the clinical characteristics, management practices, observation duration, and occurrence of biphasic reactions among children presenting with anaphylaxis to a tertiary pediatric emergency department (PED). Methods: This single-center retrospective observational study included children aged 0–18 years who presented with anaphylaxis to a tertiary PED between January 2014 and December 2024. Potential cases identified through ICD-10 codes and PED intramuscular adrenaline administration records were reviewed to confirm the diagnosis according to established criteria. Demographic and clinical characteristics, suspected triggers, treatments, observation duration, and biphasic reactions were evaluated. Results: Seventy anaphylaxis episodes in 68 patients were analyzed. The median age was 93.5 months (IQR, 50–156). Food (32.9%) and insect stings (28.6%) were the most common suspected triggers, followed by drug/vaccine-related triggers (18.6%) and allergen immunotherapy (11.4%). Adrenaline was administered in 94.3% of episodes, and intravenous fluid therapy in 50.0%. Central nervous system involvement and age-adjusted hypotension were more frequent among episodes receiving intravenous fluid therapy (p = 0.004 and p < 0.001, respectively). The median PED observation duration was 5.5 h (IQR, 2–8). Biphasic reactions occurred in three episodes (4.3%), all within three hours after initial symptom resolution. Conclusions: In this tertiary PED cohort, adrenaline administration was frequent, and biphasic reactions were uncommon and occurred during the early observation period. Given the small number of biphasic reactions, these findings should be interpreted as descriptive and are insufficient to determine the optimal observation duration.
7 April 2026 in The Journal of Allergy and Clinical Immunology: In Practice
Background: Maternal diabetes disrupts fetal lung development. This study aimed to compare cord blood adipokines and neonatal respiratory function tests (RFTs) in healthy neonates of diabetic mothers versus controls. Methods: This prospective cohort study involved term, healthy newborns born to diabetic mothers (NDM group, n = 37) and sex‐ and age‐matched healthy controls (NHC group, n = 40). RFTs were performed at 48 h of life using tidal breath analysis (TBA). The assessed parameters included time to peak tidal expiratory flow (TPTEF), the ratio of TPTEF to total expiratory time (TPTEF/TE), the ratio of volume to peak expiratory flow to total expiratory volume (VPTEF/VE), reflecting early airway mechanics. Low respiratory function was defined as TPTEF/TE below 35%. Cord blood adipokines including leptin, ghrelin, and adiponectin levels were measured by ELISA. Results: The NDM group exhibited lower TPTEF, TPTEF/TE, and VPTEF/VE ratio TBA parameters ( p < .001 for all). Cord blood leptin levels were higher in the NDM group, while ghrelin and adiponectin levels were lower ( p = .002, p < .001 and p < .001 respectively). Ghrelin levels were positively correlated with TPTEF ( ρ = 0.231, p = .043), TPTEF/TE ( ρ = 0.264, p = .020), and VPTEF/VE ( ρ = 0.236, p = .038). Decision tree analysis identified ghrelin as the primary discriminator of low RFTs, with an accuracy of 74%. Conclusion: Clinically healthy term infants born to diabetic mothers exhibit measurable impairments in RFTs at birth, accompanied by altered cord blood adipokine profiles, suggesting a potential role for adipokines as early biomarkers of respiratory vulnerability. image